# KEYNOTE-629 (NCT03284424)

> Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03284424
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Squamous Cell Carcinoma
- Interventions: Pembrolizumab
- Enrollment: 159
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on KEYNOTE-629 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 YouTube videos
- 5 podcast episodes
- 4 posts on X

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=keynote-629-nct03284424

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03284424", "email": "<work email>"}; the inbox owner confirms by the emailed link.